Cidara Therapeutics Stock (NASDAQ:CDTX)
Previous Close
$221.38
52W Range
$15.22 - $221.42
50D Avg
$187.66
200D Avg
$84.67
Market Cap
$5.61B
Avg Vol (3M)
$1.37M
Beta
1.53
Div Yield
-
CDTX Company Profile
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
CDTX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| IRON | Disc Medicine, Inc. |
| ADPT | Adaptive Biotechnologies Corporation |
| CPRX | Catalyst Pharmaceuticals, Inc. |
| BEAM | Beam Therapeutics Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |
| ZLAB | Zai Lab Limited |
| LEGN | Legend Biotech Corporation |
| SRRK | Scholar Rock Holding Corporation |